Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

efavirenz/emtricitabine/tenofovir disoproxil fumarate

A fixed combination of efavirenz, a non-nucleoside reverse transcriptase (RT) inhibitor (NNRTI); emtricitabine, a nucleoside RT inhibitor (NRTI) analog of cytidine; and tenofovir disoproxil fumarate, an NRTI analog of adenosine monophosphate, that is used to treat human immunodeficiency virus (HIV) infection. Upon oral administration, efavirenz, emtricitabine, and tenofovir disoproxil fumarate inhibit the activity of HIV RT by competing with natural deoxyribonucleosides for incorporation into the growing viral DNA chain resulting in early chain termination. This interferes with the generation of DNA copies of viral RNA, which is necessary for the synthesis of new virions.
Synonym:efavirenz/emtricitabine/tenofovir
US brand name:Atripla
Abbreviation:EFV/FTC/TDF
Search NCI's Drug Dictionary